Approved Risk Evaluation and Mitigation Strategies (REMS)

Contact Us | REMS Basics | Gov Delivery Get REMS Email Alerts | Reports & Data Files

Trulicity (dulaglutide)
BLA #125469
REMS last update: 04/19/2017



What is the purpose of the REMS?

The goal of the TRULICITY REMS is to mitigate the potential risk of medullary thyroid carcinoma and the risk of pancreatitis associated with the use of TRULICITY by:

  1. Informing healthcare providers (HCPs) about the potential risk of medullary thyroid carcinoma associated with TRULICITY.
  2. Informing HCPs about the risk of pancreatitis associated with TRULICITY.

What do participants need to know?

Healthcare providers should read the relevant Medication Guide or communication materials included in the product-specific approved REMS to learn about the risk(s). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website See Disclaimer page regarding links to external sites

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Trulicity REMS, see the DailyMed link(s).
Material Name Material Name Link
REMS document (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Trulicity_2017-04-19_REMS_Document.pdf
REMS Factsheet (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Trulicity_2017-04-19_REMS_Factsheet.pdf
REMS full (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Trulicity_2017-04-19_Full.pdf
REMS Letter for Healthcare Providers (Email Version) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Trulicity_2017-04-19_REMS_Letter_for_Healthcare_Providers_Email_Version.pdf
REMS Letter for Healthcare Providers (Print Version) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Trulicity_2017-04-19_REMS_Letter_for_Healthcare_Providers_Print_Version.pdf
REMS Letter for Professional Societies (Email Version) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Trulicity_2017-04-19_REMS_Letter_for_Professional_Societies_Email_Version.pdf
REMS Letter for Professional Societies (Print Version) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Trulicity_2017-04-19_REMS_Letter_for_Professional_Societies_Print_Version.pdf
REMS Website Screenshot (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Trulicity_2017-04-19_REMS_Website_Screenshot.pdf

What updates have been made to the REMS?

Date Summary of change
04/19/2017 Revised to make an editorial change.
07/27/2015 Modified to conform the REMS to the safety labeling changes approved on March 9, 2015, in sBLA No.001 in the REMS document, REMS Letters, REMS Factsheet, and REMS webpage.
09/18/2014 Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English